Chimeric antigen receptor (CAR) T-cell therapy can cure certain types of blood cancer, but cost and a general lack of ...

According to a report written by sister publication Dermatology Times (DT) in November, research from the 2025 Inflammatory Skin Disease Summit noted that itch can signal inflammation in the body.

In this interview, George Eastwood, executive director of the Emily Whitehead Foundation and CAR T Vision steering committee member discusses barriers and strategies for expanding access to CAR T-cell ...

Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with ...

Each Sunday we feature a highlight reel of various articles posted on our website that week.

He also discussed how linvoseltamab could fit into care for newly diagnosed patients. With several treatment options already available, he said linvoseltamab may become another strong choice, ...

The chief medical officer of Genetix Biotherapeutics, formerly known as Bluebird bio, discusses timelines and operational ...

Robert Orlowski, M.D., Ph.D., of the MD Anderson Cancer Center shared early results from the LINKER-MM1 trial with Managed Healthcare Executive, which is testing linvoseltamab in people newly ...

Researchers said future studies could help refine the use of Jaypirca alone or in combination with other therapies as a frontline treatment. She added that they are also continuing to investigate ...

From 2017 to 2024, newly diagnosed multiple myeloma (MM) patients rapidly received quadruplet therapies over triplets, with ...

Imfinzi is the first perioperative immunotherapy approved for resectable gastric/GEJ cancers, offering a new treatment ...

Nanotube pathways enhance drug delivery in bladder cancer, improving hydroxycamptothecin penetration and efficacy in animal ...